Back

Description of flecainide usage from 2005-2018 in the Danish population

3 April 2022 (08:20 - 20:00)
Organised by:
Congress Presentation Part of: ePosters Day 1 Antiarrhythmic Drug Treatment EHRA Premium Access EHRA 2022

About the speaker

Photo
Mr Emil Alexander Krogager

Gentofte (Denmark)

128 More presentations in this session

Presentation thumbnail
Detection of endo-epicardial atrial low-voltage areas using unipolar and omnipolar voltage mapping
Mr M. Van Schie (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Atrial high-rate episodes in patients with devices without a history of atrial fibrillation
Doctor I. Doundoulakis (Brussels, BE)
Abstract Slides
Presentation thumbnail
The impact of different fat depots in the body on the progression of atrial fibrillation - data from RACE V
Doctor V. Weberndoerfer (Maastricht, NL)
Abstract Slides
Presentation thumbnail
Pulsed field ablation of atrial fibrillation: recurrence rate after first pulmonary vein isolation and first insights into durability at redo procedures
Mr T. Kueffer (Bern, CH)
Abstract Slides
Presentation thumbnail
Early mortality and complications following first-time catheter ablation of atrial fibrillation in a nationwide cohort
Doctor C. Witt (Aarhus, DK)
Abstract Slides

Access the full session

Session thumbnail
ePosters Day 1

The Event

Event poster

EHRA 2022

3 April 2022 08:20 CET
You may be interested in
thumbnail
Congress Presentation
Increasing use of amiodarone in Norway
27 August 2021
thumbnail
Congress Presentation
Flecainide in the treatment of high premature ventricular contractions burden: preliminary results from the UNIFLECA study
13 April 2026
thumbnail
Congress Presentation
Dyskalemias in hypertensive patients treated with combination of antihypertensive drugs: a nested case-control study using danish national registries
1 September 2019
thumbnail
Congress Presentation
Virtual and in-person consultations for patients diagnosed with atrial fibrillation, heart failure, pulmonary embolism or acute coronary syndrome: a nationwide cohort study
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources